Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corporation (CDXC) on October 10, 2022. The filing discloses the entry into a material definitive agreement and a concurrent securities purchase transaction with Société des Produits Nestlé SA ("NHSc").
Key Financial Metrics and Transaction Details
- Securities Purchase: NHSc agreed to purchase 3,816,794 shares of ChromaDex common stock for an aggregate price of $5 million.
- Supply Commitment: NHSc committed to an initial purchase of nicotinamide riboside chloride ("NRCL") totaling $1.975 million.
- Revenue Structure: Future NRCL sales will be priced at tiered rates based on volume. Additionally, NHSc will pay royalties at low-single-digit percentages on worldwide net sales of approved products and one-time milestone payments in the low seven figures upon achieving specific sales targets.
- Contract Term: The Supply Agreement has an initial term of five years with automatic one-year extensions contingent on minimum purchase volumes.
Material Changes and Strategic Developments
The filing represents a significant expansion of the commercial relationship between ChromaDex and NHSc (successor to NESTEC Ltd.). Key changes include:
- Expanded Rights: Unlike the original 2018 agreement, NHSc now holds the non-exclusive right to manufacture, market, distribute, and sell products using NRCL for human use in medical nutritional, functional food/beverage, and multi-ingredient dietary supplement categories globally (with specific exclusions).
- Exclusivity: NHSc and its affiliates have exclusive rights to purchase NRCL from ChromaDex.
- Capital Injection: The $5 million equity purchase provides immediate liquidity to ChromaDex.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement secures a long-term revenue stream through guaranteed initial purchases, tiered pricing, and potential milestone payments. The automatic extension clauses suggest management anticipates sustained demand.
Risks and Termination:
- Termination for Convenience: NHSc may terminate the Supply Agreement at any time with 12 months' advance written notice.
- Force Majeure: Either party may terminate if a force majeure event continues for 90 days or is expected to continue for more than 180 days.
- Bankruptcy: Immediate termination is permitted if either party files for bankruptcy or becomes insolvent.
Investor Verification Checklist
- Verify the exact volume-weighted average price used to calculate the $5 million share purchase.
- Review the full text of the Supply Agreement (to be filed in the 2022 Form 10-K) for specific excluded territories and ingredient combinations.
- Confirm the specific "low seven figures" milestone thresholds and the "low-single-digit" royalty percentages.
- Assess the impact of the 12-month termination notice provision on the stability of future revenue projections.